In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model

Cancer Immunology, Immunotherapy

Volumn 61, Issue 10, 2012, Pages 1617-1626

  Pardo, Alessa ^a   Stöcker, Michael ^a   Kampmeier, Florian ^a   Melmer, Georg ^b   Fischer, Rainer ^c   Thepen, Theo ^c   Barth, Stefan ^a,c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b PharmedArtis GmbH   (Germany)

^c FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

EGF receptor; Fluorescence imaging; Immunotherapy; Katushka; ScFv immunotoxin; Treatment response

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCENT DYE; KAT2 PROTEIN; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONJUGATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLUORESCENCE IMAGING; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; MULTIPLE CYCLE TREATMENT; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CARCINOMA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EXOTOXINS; FEMALE; HUMANS; IMMUNOTOXINS; LUMINESCENT PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR IMAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS; SPECTROSCOPY, NEAR-INFRARED; TRANSFECTION; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867581008     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1219-3     Document Type: Article

References (44)

1. Contag PR (2002) Whole-Animal cellular and molecular imaging to accelerate drug development. Drug Discov Today 7:555-562
2. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC (1994) Green fluorescent protein as a marker for gene expression. Science 263:802-805
3. Alford R, Ogawa M, Choyke PL, Kobayashi H (2009) Molecular probes for the in vivo imaging of cancer. Mol Biosyst 5:1279-1291
4. Gong H, Kovar J, Little G, Chen H, Olive DM (2010) In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore. Neoplasia 12:139-149
5. Weissleder R (2001) A clearer vision for in vivo imaging. Progress continues in the development of smaller, more penetrable probes for biological imaging. Nat Biotechnol 19:316-317
6. Shcherbo D, Merzlyak EM, Chepurnykh TV, Fradkov AF, Ermakova GV, Solovieva EA et al (2007) Bright far-red fluorescent protein for whole-body imaging. Nat Methods 4:741-746
7. Haigler H, Ash JF, Singer SJ, Cohen S (1978) Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc Natl Acad Sci USA 75:3317-3321
8. Tolmachev V, Rosik D, Wallberg H, Sjoberg A, Sandstrom M, Hansson M et al (2010) Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In- DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imag 37:613-622
9. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R et al (2005) Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11:6270-6279
10. Shao W, Zhao S, Liu Z, Zhang J, Ma S, Sato JD et al (2006) Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C. Biochem Biophys Res Commun 349:816-824
11. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R (2003) FDA drug approval summary: Gefitinib (ZD1839)(Iressa (R)) tablets. Oncologist 8:303-306
12. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R (2005) FDA drug approval summary: erlotinib (Tarceva (R)) tablets. Oncologist 10:461-466
13. Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S (2010) Cetuximab: from bench to bedside. Curr Cancer Drug Targets 10:80-95
14. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R (2007) FDA drug approval summary: panitumumab (Vectibix). Oncologist 12:577-583
15. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM (2005) Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11:397-405
16. Bruell D, Stocker M, Huhn M, Redding N, Kupper M, Schumacher P et al (2003) The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol 23:1179-1186
17. Bruell D, Bruns CJ, Yezhelyev M, Huhn M, Muller J, Ischenko I et al (2005) Recombinant anti-EGFR immunotoxin 425 (scFv)- ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med 15:305-313
18. Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinkothe T et al (2000) Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 95:3909-3914
19. Huhn M, Sasse S, Tur MK, Matthey B, Schinkothe T, Rybak SM, et al. (2001) Human angiogenin fused to human CD30 Ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 61:8737-8742
20. Tur M, Huhn M, Thepen T, Stocker M, Krohn R, Vogel S et al (2003) Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res 63:8414-8419
21. Stahnke B, Thepen T, Stocker M, Rosinke R, Jost E, Fischer R et al (2008) Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 7:2924-2932
22. Tur MK, Neef I, Jost E, Galm O, Jager G, Stocker M et al (2009) Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells. J Immunother 32:431-441
23. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559-565
24. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ (2007) Immunotoxin treatment of cancer. Annu Rev Med 58:221-237
25. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, Fitzgerald DJ et al (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345:241-247
26. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM et al (2010) Anti-CD22 immunotoxin RFB4(dsFv)- PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 16:1894-1903
27. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
28. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136:823-837
29. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL (2009) Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28:3801-3813
30. Arteaga CL (2003) EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol 21:289s-291s
31. Kampmeier F, Ribbert M, Nachreiner T, Dembski S, Beaufils F, Brecht A et al (2009) Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-Alkylguanine DNA alkyltransferase. Bioconjug Chem 20:1010-1015
32. Kampmeier F, Niesen J, Koers A, Ribbert M, Brecht A, Fischer R et al (2010) Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein. Eur J Nucl Med Mol Imag 37:1926-1934
33. Matthey B, Engert A, Klimka A, Diehl V, Barth S (1999) A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins. Gene 229:145-153
34. Ribbert T, Thepen T, Tur MK, Fischer R, Huhn M, Barth S (2010) Improved efficacy by increased valency, both in vitro, as well as in vivo in a chronic cutaneous inflammation model in hCD64 transgenic mice. Br J Dermatol 162:1-3
35. Kapp U, Wolf J, Von Kalle C, Tawadros S, Rottgen A, Engert A et al (1992) Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice. Ann Oncol 3:S21- S23
36. Stocker M, Tur MK, Sasse S, Krußmann A, Barth S, Engert A (2003) Secretion of functional anti-CD30-Angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif 28:211-219
37. Johansen PB (1981) Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol 5:267-270
38. Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M, Kawanishi S (2005) Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 76:1439-1453
39. Ajaj KA, Graeser R, Fichtner I, Kratz F (2009) In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother Pharmacol 64:413-418
40. Jensen MM, Jørgensen JT, Binderup T, Kjaer A (2008) Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDGmicroPET or external caliper. BMC Med Imag 8:16
41. He X, Nie H, Wang K, Tan W, Wu X, Zhang P (2008) In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles. Anal Chem 80:9597-9603
42. Kobayashi H, Longmire MR, Ogawa M, Choyke PL (2011) Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chem Soc Rev 40:4626-4648
43. Barrett T, Koyama Y, Hama Y, Ravizzini G, Shin IS, Jang BS et al (2007) In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res 13:6639-6648
44. Urano Y, Asanuma D, Hama Y, Koyama Y, Barrett T, Kamiya M et al (2009) Selective molecular imaging of viable cancer cells with pH-Activatable fluorescence probes. Nat Med 15:104-109